Gilead Sciences (NASDAQ:GILD) Price Target Raised to $158.00

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by Truist Financial from $150.00 to $158.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the stock. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. HSBC increased their target price on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Finally, Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $159.26.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $151.17 on Wednesday. The business has a 50-day moving average of $145.13 and a 200 day moving average of $136.72. Gilead Sciences has a 12 month low of $114.02 and a 12 month high of $157.29. The stock has a market capitalization of $187.44 billion, a price-to-earnings ratio of -56.62 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 EPS. As a group, sell-side analysts forecast that Gilead Sciences will post -0.48 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00. Following the completion of the transaction, the chief executive officer owned 566,683 shares in the company, valued at $83,812,415.70. This represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock valued at $14,940,540 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth $15,393,785,000. Legal & General Group Plc acquired a new position in Gilead Sciences in the second quarter valued at $1,316,606,000. Deutsche Bank AG acquired a new position in Gilead Sciences in the second quarter valued at $918,387,000. Boston Partners purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $517,808,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $448,021,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst support remains broadly favorable. JPMorgan said Gilead’s stock price is expected to rise, while Truist Financial raised its price target. Morgan Stanley also maintained a buy rating, despite lowering its expectations for the shares. JPMorgan analyst expects Gilead stock to rise Truist raises Gilead price target Morgan Stanley buy rating
• Positive Sentiment: Cantor Fitzgerald reaffirmed its overweight rating and set a $155 price target, implying limited additional upside but reinforcing the view that Gilead remains attractive relative to the broader sector.
• Positive Sentiment: Gilead signed a five-year DevOps agreement with Cognizant to improve technology and operational processes. Separately, its oncology collaboration with Nurix was extended by two years, preserving the potential for milestone payments and royalties tied to future therapies. Gilead Cognizant agreement Gilead Nurix collaboration extension
• Neutral Sentiment: The reported October short-interest figure is zero shares, producing a zero-day short-interest ratio. This unusually low reading may reflect a reporting or data issue rather than a meaningful change in investor positioning.
• Negative Sentiment: RBC raised its target from $123 to $126 but retained a sector-perform rating; the target remains materially below the current share price. Morgan Stanley’s lower expectations and modest after-hours weakness also highlight near-term valuation risk. RBC Gilead price target

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.